Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading

被引:31
作者
Uzun, O [1 ]
Arikan, S
Kocagöz, S
Sancak, B
Unal, S
机构
[1] Hacettepe Univ, Sch Med, Dept Med, Infect Dis Sect, TR-06100 Ankara, Turkey
[2] Hacettepe Univ, Sch Med, Dept Microbiol & Clin Microbiol, TR-06100 Ankara, Turkey
关键词
D O I
10.1016/S0732-8893(00)00177-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Voriconazole is a promising azole effective against a variety of fungi, including yeasts. In this study, we tested in vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against some ATCC and reference strains and 250 clinical yeast isolates. We also evaluated the effect of time of reading on MIC results. Voriconazole was the most active agent against Candida and Trichosporon isolates, including the putatively fluconazole-resistant C. krusei (MIC90 0.25 mu g/ml) and C. glabrata (MIC90 0.5 mu g/ml). Amphotericin B MICs were scattered in a considerably narrow range in both RPMI 1640 and Antibiotic Medium 3. MICs at 24 hours and 48 hours were similar in general for all antifungals tested. The highest percentage of strains that showed 24-hour and 48-hour MICs within +/-1-log(2) dilution was observed for amphotericin B tested in RPMI (99%), and the lowest for amphotericin B tested in Antibiotic Medium 3 (80%). In conclusion, voriconazole is very effective against a wide spectrum of Candida species and 24-hour readings could substitute 48-hour MIC evaluation. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:101 / 107
页数:7
相关论文
共 41 条
[1]   FLUCONAZOLE SUSCEPTIBILITY TESTING OF CANDIDA-ALBICANS - MICROTITER METHOD THAT IS INDEPENDENT OF INOCULUM SIZE, TEMPERATURE, AND TIME OF READING [J].
ANAISSIE, E ;
PAETZNICK, V ;
BODEY, GP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (08) :1641-1646
[2]   Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: An eight-center collaborative study [J].
Anaissie, EJ ;
Paetznick, VL ;
Ensign, LG ;
EspinelIngroff, A ;
Galgiani, JN ;
Hitchcock, CA ;
LaRocco, M ;
Patterson, T ;
Pfaller, MA ;
Rex, JH ;
Rinaldi, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2387-2391
[3]   Comparison of Etest, microdilution and colorimetric dilution with reference broth macrodilution method for antifungal susceptibility testing of clinically significant Candida species isolated from immunocompromised patients [J].
Arikan, S ;
Gur, D ;
Akova, M .
MYCOSES, 1997, 40 (7-8) :291-296
[4]   In vitro studies of two triazole antifungal agents (Voriconazole [UK-109,496] and fluconazole) against Candida species [J].
Barry, AL ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1948-1949
[5]   Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species [J].
Belanger, P ;
Nast, CC ;
Fratti, R ;
Sanati, H ;
Ghannoum, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1840-1842
[6]  
BODEY GP, 1984, AM J MED, V77, P13
[7]  
BODEY GP, 1992, CLIN INFECT DIS S1, V14, P161
[8]   FLUCONAZOLE-RESISTANT CANDIDA-ALBICANS [J].
BOKEN, DJ ;
SWINDELLS, S ;
RINALDI, MG .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (06) :1018-1021
[9]   In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients [J].
Chávez, M ;
Bernal, S ;
Valverde, A ;
Gutierrez, MJ ;
Quindós, G ;
Mazuelos, EM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (05) :697-700
[10]   Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain [J].
Cuenca-Estrella, M ;
Díaz-Guerra, TM ;
Mellado, E ;
Monzón, A ;
Rodríguez-Tudela, JL .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (06) :432-435